Transport properties of pancreatic cancer describe gemcitabine delivery and response

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1525-1536

  Koay, Eugene J ^a,b   Truty, Mark J ^c   Cristini, Vittorio ^d   Thomas, Ryan M ^e,f   Chen, Rong ^a   Chatterjee, Deyali ^a   Kang, YA'An ^a   Bhosale, Priya R ^a   Tamm, Eric P ^a   Crane, Christopher H ^a   Javle, Milind ^a   Katz, Matthew H ^a   Gottumukkala, Vijaya N ^a   Rozner, Marc A ^a   Shen, Haifa ^b   Lee, Jeffery E ^a   Wang, Huamin ^a   Chen, Yuling ^a   Plunkett, William ^a   Abbruzzese, James L ^g   Wolff, Robert A ^a   Varadhachary, Gauri R ^a   Ferrari, Mauro ^b   Fleming, Jason B ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DNA; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DNA INTERACTION; DRUG RESPONSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TRANSPORT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MALE; MICROVASCULATURE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RESECTABLE CANCER; STROMA CELL; SURVIVAL RATE; THROMBOCYTOPENIA; TISSUE CHARACTERIZATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT, ACTIVE; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DNA ADDUCTS; DNA, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897503883     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73455     Document Type: Article

References (40)

1. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology. 2005;128(6):1642-1654. (Pubitemid 40692557)
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049-1057. (Pubitemid 38410779)
3. Olive KP, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
4. Beatty GL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612- 1616.
5. Frieboes HB, Chaplain MA, Thompson AM, Bearer EL, Lowengrub JS, Cristini V. Physical oncology: a bench-to-bedside quantitative and predictive approach. Cancer Res. 2011;71(2):298-302.
6. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559-593.
7. Michor F, Liphardt J, Ferrari M, Widom J. What does physics have to do with cancer? Nat Rev Cancer. 2011;11(9):657-670.
8. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010;28(4):181-188.
9. Neesse A, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861-868.
10. Edgerton ME, Chuang YL, Macklin P, Yang W, Bearer EL, Cristini V. A novel, patient-specific mathematical pathology approach for assessment of surgical volume: application to ductal carcinoma in situ of the breast. Anal Cell Pathol (Amst). 2011;34(5):247-263.
11. Pascal J, Bearer EL, Wang Z, Koay EJ, Curley SA, Cristini V. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proc Natl Acad Sci U S A. 2013;110(35):14266-14271.
12. Pries AR, Hopfner M, le Noble F, Dewhirst MW, Secomb TW. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer. 2010;10(8):587-593.
13. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418-429.
14. Stylianopoulos T, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012;109(38):15101-15108.
15. Farrell JJ, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136(1):187-195.
16. McNulty NJ, Francis IR, Platt JF, Cohan RH, Korobkin M, Gebremariam A. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology. 2001;220(1):97-102. (Pubitemid 32577966)
17. Morinaga S, et al. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol. 2012;19(suppl 3):S558-S564.
18. Zhao Q, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16(1):29-37.
19. Evans DB, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496-3502.
20. Varadhachary GR, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487-3495.
21. Chatterjee D, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118(12):3182-3190.
22. National Cancer Institute. Cancer Trends Progress Report 2011/2012. NIH Web site. http://progressreport.cancer.gov/. Accessed January 31, 2014.
23. Nagaraju GP, El-Rayes BF. SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Cancer Lett. 2013;328(1):10-17.
24. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res. 2012;18(16):4277-4284.
25. Kindler HL, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12(3):256-262.
26. Schmidt J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30(33):4077-4083.
27. Crane CH, Iacobuzio-Donahue CA. Keys to personalized care in pancreatic oncology. J Clin Oncol. 2012;30(33):4049-4050.
28. Pascal J, et al. Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. ACS Nano. 2013;7(12):11174-11182.
29. Tofts PS, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223-232. (Pubitemid 29463104)
30. Wasser K, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol. 2003;13(1):80-87. (Pubitemid 36790494)
31. Park MS, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology. 2009;250(1):110-117.
32. Kawada N, et al. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J Hepatobiliary Pancreat Sci. 2012;19(6):717-722.
33. Eisbruch A, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol. 2001;19(3):792-799. (Pubitemid 32119095)
34. Taghian AG, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol. 2005;23(9):1951-1961. (Pubitemid 46211374)
35. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol. 2006;24(8):985-995. (Pubitemid 44215393)
36. Tamm EP, Balachandran A, Bhosale P, Szklaruk J. Update on 3D and multiplanar MDCT in the assessment of biliary and pancreatic pathology. Abdom Imaging. 2009;34(1):64-74.
37. Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology. 2010;256(1):32-61.
38. Varadhachary GR, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035-1046. (Pubitemid 44337962)
39. Evans D, Lee J, Tamm E. Pancreaticoduodenectomy (Whipple Operation) and total pancreatectomy for cancer. In: Fischer JF, ed. Fischer's Mastery of Surgery. 5th ed. Philadelphia, Pennsylvania, USA: Lippincott Williams and Wilkins; 2007:Chapter 113.
40. Wickremsinhe ER, et al. Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement. Anal Chem. 2010;82(15):6576-6583.